Genenta Science (NASDAQ:GNTA) Shares Down 1.3% – Here’s Why

Shares of Genenta Science S.p.A. (NASDAQ:GNTA) were down 1.3% on Friday . The stock traded as low as $3.51 and last traded at $3.76. Approximately 22,483 shares traded hands during mid-day trading, an increase of 43% from the average daily volume of 15,753 shares. The stock had previously closed at $3.81.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and issued a $25.00 price objective on shares of Genenta Science in a report on Wednesday, October 2nd.

Genenta Science Trading Down 1.3 %

The company’s 50-day simple moving average is $4.88 and its 200 day simple moving average is $4.55.

Institutional Trading of Genenta Science

A hedge fund recently bought a new stake in Genenta Science stock. AlTi Global Inc. purchased a new stake in shares of Genenta Science S.p.A. (NASDAQ:GNTA) in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 200,288 shares of the company’s stock, valued at approximately $621,000. AlTi Global Inc. owned about 1.10% of Genenta Science as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 15.13% of the company’s stock.

About Genenta Science

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter.